By Maryanne Demasi at Brownstone dot org.
A cache of internal emails obtained from within the US National Institutes of Health has exposed years of strategic planning for future pandemics involving governments, foundations, international organisations, and pharmaceutical companies.
The documents, stretching back to at least 2016, show that Dr Francis Collins, Director of the NIH from 2009 to 2021, was at the centre of these efforts.
In that role, he oversaw the allocation of the agency's substantial research budget, which ran into tens of billions of dollars annually.
The emails reveal Collins working closely with the Gates Foundation, Wellcome Trust, World Bank, World Economic Forum, the African Academy of Sciences, and major pharmaceutical companies to strengthen research infrastructure, regulatory readiness, and international coordination well before Covid appeared.
For the public, the Covid response was presented as an unexpected crisis. Governments appeared to be making difficult decisions while navigating profound uncertainty.
But these emails tell a different story.
Many of the same organisations that later shaped the Covid response had already spent years building capacity, influence, and institutional power under Collins' leadership.
Billions of dollars flowed through the sprawling network. Careers were built around it, reputations depended on it, and political and financial interests became invested in its success.
By the time Covid arrived, much of the framework was already in place.
The planning gained momentum after the 2014-16 Ebola outbreak highlighted gaps in global preparedness. Vaccines took too long to develop, trials were hard to organise, and funding was fragmented.
The response, according to the emails, was to build permanent capacity in advance rather than react after the fact.
One major outcome was the launch of the Coalition for Epidemic Preparedness Innovations (CEPI) in 2017 at the World Economic Forum (WEF), which hosts an annual gathering of globalist elites in Davos, Switzerland.
CEPI focused on vaccines against emerging infectious diseases and became a key part of pandemic planning alongside the NIH and major foundations.
During Covid, CEPI became one of the major funders of vaccine development, investing hundreds of millions of dollars in multiple vaccine platforms that eventually led to vaccines from companies such as Moderna.
The internal documents show there was particular focus on expanding research capacity in Africa, a region long criticised for weak regulatory oversight and less stringent enforcement of clinical trial standards.
Collins chaired a 2017 WEF meeting on building a sustainable biomedical research enterprise in Sub-Saharan Africa.
The call brought together senior figures from the Wellcome Trust and other partners to advance plans for major new investment, including a proposed $10 billion African science, technology and innovation fund.
Collins appeared keen to ensure there was no confusion about who was in charge. After one teleconference with the WEF he wrote to his NIH colleagues:
"In the last call there was a bit of confusion about who was leading (NIH or WEF). I think this time it should be me. Agree?"
By 2018, senior pharmaceutical executives were discussing long-term investments in infrastructure designed to endure well beyond any single outbreak.
One project focused on SMART Vaccines, a decision-support tool designed to help governments and funders systematically prioritise vaccine candidates and guide investment decisions ahead of future outbreaks.
Workshops for the project brought together a who's who of global health institutions, government agencies, philanthropic foundations, vaccine manufacturers, and international organisations.
The language of the initiative emphasised "consensus-building" and "public-private partnerships," to keep major organisations and stakeholders in lockstep—many of whom would later play influential roles during Covid.
By 2019, the cor...